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SUMMARY – In this article, we outline the latest guidelines published by the American Heart 
Association on sexual activity in patients with coronary artery disease, heart failure, structural heart 
diseases, arrhythmias, implanted pacemakers or cardioverter defi brillators, as well as on treatment 
 options of sexual dysfunction. Sexual activities are similar to mild/moderate physical activity during a 
short period. Most patients are recommended to involve in sexual activity after prior comprehensive 
evaluation of physical condition. Th ose with stable cardiac symptoms and good functional capacity are 
at a low risk of adverse cardiovascular events, and others require treatment or stabilization before 
 involving in sexual activity. Stress testing is useful in evaluating safety of sexual activity in patients with 
questionable or undetermined risk. Treatment of sexual dysfunction includes counseling of patients and 
their sexual partners, and drug treatment with phosphodiesterase inhibitors (sildenafi l, tadalafi l, var-
denafi l) which have been demonstrated to be safe and eff ective, in men, and with serotonin reuptake 
inhibitors (fl ibanserin) and local vaginal estrogen administration in women. In conclusion, in routine 
clinical practice, patients should be approached individually and multidisciplinarily in order to detect 
and eliminate the factors that interfere with normal sexual activities and disturb the quality of life.
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Introduction
Erectile and sexual dysfunction in males and fe-
males (decreased libido, inability to achieve orgasm, 
dyspareunia) are independent predictors of adverse 
cardiovascular events and poorer quality of life (QoL). 
Both entities have common causal factors such as  older 
age, arterial hypertension, obesity, disorders of glucose 
and lipid metabolism, metabolic syndrome, smoking 
and sedentary lifestyle, which individually or synergis-
tically lead to endothelial dysfunction of cardiovascu-
lar and reproductive organs. It takes 2 to 5 years from 
sexual dysfunction to evident appearance of some of 
undesirable cardiovascular events (acute coronary 
event, stroke, peripheral arterial disease). It could be 
explained by the smaller caliber of sexual organ blood 
vessels and thus earlier clinical manifestations of en-
dothelial dysfunction1,2. Th is article brings a review of 
the latest American Heart Association (AHA) guide-
lines and other relevant literature about sexual activity 
(SA) in patients with various cardiac pathology, and 
treatment options for sexual dysfunction3.
Sexual Activity and Acute 
Cardiovascular Response
During sexual foreplay and arousal, the values of 
blood pressure (BP) and heart rate (HR) rise and reach 
maximum during orgasm. After that, they rapidly de-
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cline to the normal values4-10. SA is equal to mild/
moderate physical activity for a short duration (climb-
ing 2 fl ights of stairs or walking briskly, i.e. with 3-4 
metabolic equivalents (METs))11. Th e values of HR 
and systolic BP are usually below 130 bpm and 170 
mm Hg, respectively6,12,13.
Due to medical or emotional reasons, or older age, 
some patients may have diffi  culty reaching orgasm and 
exert greater demand on their cardiovascular system14.
General Recommendations about Sexual Activity 
in Various Cardiac Diseases
Initial clinical evaluation in patients with cardio-
vascular disease (CVD) is necessary before initiating 
or resuming SA, which is acceptable in a group of sub-
jects with no or minimal symptoms during routine ac-
tivities and low risk of cardiovascular complica-
tions3,15-18. Th is group consists of patients with Cana-
dian Classifi cation System (CCS) class I or II angina; 
New York Heart Association (NYHA) class I or II 
heart failure; mild to moderate valve disease; previous 
myocardial infarction; successful coronary revascular-
ization; most types of congenital heart disease; and 
ability to achieve ≥3-5 METs during exercise stress 
testing without angina, ischemic electrocardiographic 
changes, hypotension, cyanosis, arrhythmia, or exces-
sive dyspnea. In patients with unstable or decompen-
sated heart disease (i.e. unstable angina, decompen-
sated heart failure (HF), uncontrolled arrhythmia, or 
signifi cantly symptomatic and/or severe valve disease), 
SA should be deferred until the patient is stabilized 
and optimally managed3. Exercise stress testing is rea-
sonable for patients who have unknown cardiovascular 
risk to assess exercise capacity and development of 
symptoms, ischemia, or arrhythmias. Accordingly, SA 
is acceptable in patients who can achieve ≥3-5 METs 
without angina, excessive dyspnea, ischemic ST-seg-
ment changes, cyanosis, hypotension or arrhythmias3,19. 
Finally, cardiac rehabilitation and regular exercise in 
patients with CVD are reasonable and can be useful in 
reducing the risk of complications during SA. It in-
creases the maximum exercise capacity and leads to 
reduction of maximal coital BP and HR13,20.
Angina pectoris
Sexual activity is possible in patients with no or 
mild angina pectoris (class I or II), while it should be 
postponed in others until their condition is stabilized 
or optimally controlled3,15-18. In patients with interme-
diate symptoms or whose risk is unknown, exercise 
stress testing can provide additional information on 
exercise tolerance and estimate the severity of isch-
emia. If the person can achieve energy consumption 
≥3-5 METs, then the risk of ischemia during SA is 
very low.
Previous myocardial infarction/coronary 
revascularization
After myocardial infarction, asymptomatic pa-
tients, those without signs of ischemia during exercise 
stress testing, and subjects with complete coronary re-
vascularization performed are at low cardiovascular 
risk during SA. Current guidelines suggest beginning 
of cardiac rehabilitation as soon as possible, and SA ≥1 
weeks after myocardial infarction3. SA may be resumed 
several days after percutaneous coronary intervention, 
or 6-8 weeks after coronary artery bypass surgery or 
non-coronary open heart surgery3,15-18,21,22. In case of 
incomplete revascularization, exercise stress testing 
may provide information on residual ischemia3.
Heart failure
Sexual activity is possible in patients with compen-
sated and/or mild HF (NYHA class I or II)3,23-26. Sexu-
al problems occur in 60%-87% of patients with HF, in-
cluding signifi cant reduction in sexual interest and ac-
tivity. Sexual dysfunction correlates with symptomatol-
ogy, but not with ejection fraction. Most patients with 
HF give priority to improving QoL (including sexual 
component) rather than survival27-32. Optimal treatment 
increases the probability of safe and satisfactory SA. Ex-
ercise improves QoL and can aff ect SA. Patients who 
have shortness of breath or fatigue during SA can be 
advised to take certain positions during intercourse that 
reduce the level of physical exertion33-35.
Valve disease
Sexual activity is acceptable only in patients with 
mild/moderate valve disease, who are asymptomatic or 
with mild symptoms, as well as in patients with normal 
function of artifi cial valves, and those who have under-
gone successful trans-catheter valve correction3.
Time to resume SA after cardiovascular surgery 
procedure is discussed below. Exercise stress testing 
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can be useful in estimating individuals with asymp-
tomatic moderate or severe aortic stenosis and those 
with other asymptomatic severe valve dysfunction. Ex-
ercise echocardiography can give other helpful infor-
mation on the physiological response to exercise3.
Arrhythmias and electrostimulation
Sudden cardiac death is very rare during SA in 
general population36-38. Th e risk of ventricular arrhyth-
mia during SA in patients with CVD, including those 
with implanted cardioverter defi brillator (ICD), does 
not seem to be greater than during comparable physi-
cal exertion or stress testing39,40. SA is acceptable for 
patients with atrial fi brillation or fl utter and good con-
trol of ventricular frequency, with properly controlled 
supraventricular tachycardia, with pacemakers, with 
ICD implanted for primary prevention, and those 
with ICD used for secondary prevention, in whom 
moderate physical activity (≥3-5 METs) does not pre-
cipitate ventricular tachycardia or fi brillation and who 
do not receive frequent multiple appropriate shocks3. 
It is not acceptable in individuals who have more de-
vice activation until arrhythmia is stabilized or is not 
under optimal control3. SA often decreases after ICD 
implantation, primarily due to concerns of patients 
and partners about the danger of cardiac arrest during 
sexual intercourse41-43. Exercise stress testing can pro-
vide proof of enough security to the patient that sexu-
al activity is unlikely to lead to the incidence or wors-
ening of arrhythmias44. Also, researches have shown 
that there is minimal risk of so-called ‘electric shock’ 
during ICD activation for partners because it is very 
small energy that rarely reaches surface of the patient’s 
body45.
Congenital heart disease
Sexual activity is acceptable for most patients who 
have no decompensated or advanced HF, symptomatic 
or severe valve disease, and uncontrolled arrhythmias3. 
Published guidelines allow unlimited physical activity 
for asymptomatic patients with closed or small atrial 
or ventricular septal defect, mild coarctation of the 
aorta, closed ductus arteriosus, and other mild congeni-
tal defects with normal right-sided heart volume with-
out pulmonary hypertension and without signifi cant 
outfl ow tract obstruction of the left or right ventri-
cle46-49. Th us, SA may be acceptable in most patients 
with congenital heart disease. It is doubtful in signifi -
cant pulmonary hypertension, cyanosis, severe outfl ow 
obstruction of left ventricle, uncontrolled arrhythmias, 
and anomalous coronary artery, which passes between 
pulmonary artery and aorta.
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a hetero-
geneous genetic heart disease and it is the most com-
mon cause of arrhythmia-related sudden cardiac death 
in young people, including athletes50,51. About 70% of 
patients with HCM have left ventricle outfl ow ob-
struction, either during rest or physiological exertion 
regardless of whether or not there are limiting symp-
toms52,53. Th e connection between physical activity and 
sudden death is to be assigned to the occurrence of 
ventricular tachycardia/fi brillation, which raises con-
cerns that strong SA may increase the risk of sudden 
death in these patients51.
However, there are no documented cases of cardiac 
arrest related to SA in that population. It is in line with 
the recommendation according to which patients with 
HCM should not participate in intense competitive 
sports or similar activities54. Th us, SA is possible in 
most patients with HCM, and it should be postponed 
in symptomatic patients with HCM until their condi-
tion is stabilized or optimally controlled3.
Cardiovascular Drugs and Sexual Function
Cardiovascular drugs that can relieve symptoms 
and improve survival should not be avoided because of 
the concern about their potential impact on sexual 
function3. If the patient complains of sexual dysfunc-
tion, then it should be evaluated whether it is associ-
ated with primary CVD, cardiovascular drug adverse 
eff ect, or it is a consequence of anxiety or depression3.
Various cardiovascular drugs can cause erectile dys-
function (ED)3. In patients who developed ED during 
treatment with thiazides and β-blockers, using Henle’s 
loop diuretics and nebivolol are reasonable alternative. 
Some males treated with spironolactone can experi-
ence antiandrogen side eff ects with compromised sex-
ual function and activity (e.g., decreased libido, ED, 
and gynecomastia), and eplerenone may be reasonable 
alternative55,56. Women treated with thiazides and al-
dosterone may have problems with vaginal lubrication 
or menstrual irregularities57,58. Studies proved positive 
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eff ect of valsartan in improving ED, including orgas-
mic function, sexual desire and satisfaction with sexual 
life in patients with arterial hypertension, especially in 
obese and diabetics. Th e basic mechanism of this ac-
tion is the inhibition of local angiotensin converting 
enzyme, but there are other indirect mechanisms. Ap-
propriate alternative is treating ED with phosphodies-
terase inhibitors (PDE5)59.
Pharmacotherapy of Sexual Dysfunction
PDE5-inhibitors
Th ese medications prevent the breakdown of cGMP 
and increase the concentration of nitrogen oxide, with 
vasodilatation and improvement of erectile func-
tion3,60-62. Tadalafi l and sildenafi l are used in patients 
with pulmonary hypertension. Th ere are several main 
facts about these drugs3,60-62, as follows: PDE5-inhibi-
tors are useful in the treatment of ED in patients with 
stable CVD; safety of treatment with PDE5-inhibi-
tors is unknown in patients with severe aortic stenosis 
or HCM; PDE5-inhibitors should be avoided in pa-
tients treated with organic nitrates; and in patients 
with chest pain and/or acute coronary syndrome, or-
ganic nitrates must be avoided within 24 hours of the 
application of sildenafi l or vardenafi l, or for 48 hours 
after using tadalafi l.
Previous studies have not proven that one drug is 
more eff ective and/or safer than the others. When 
used with other cardiovascular drugs, PDE5-inhibi-
tors could be associated with symptomatic hypoten-
sion (alpha-blockers) and prolongation of QT-inter-
val3,60,62.
In 2015, Food and Drug Administration (FDA) 
approved fl ibanserin (selective serotonin reuptake in-
hibitor, SSRI) for treating sexual dysfunction in pre-
menopausal women63-67. It can be caused by mental 
and/or physical factors such as stress and hormonal 
changes during the woman’s life. With the exception 
of hypotension and syncope, especially in combination 
with alcohol or liver enzyme CYP3A4-inhibitors, the 
drug has been proven to be generally safe for use 
through testing on more than 11,000 women.
Local estrogen therapy
Estrogen treatment through vagina or vulva is ef-
fective for alleviating symptoms of vaginal atrophy and 
dyspareunia, which usually occur in menopause and 
postmenopause3,68. Oral administration of estrogen 
and progesterone may lead to increased cardiovascular 
risk, which has been excluded with local estrogen ther-
apy. Moreover, by vaginal application, systemic absorp-
tion is minimal by vaginal application and even lower 
by vulva, so there is no noticeable impact on cardiovas-
cular risk69-71.
Herbal drugs
It may be reasonable to warn patients with CVD of 
the potential adverse events with the use of herbal 
medications with unknown ingredients, taken for the 
treatment of sexual dysfunction3. Some of these may 
contain compounds (e.g., PDE5-inhibitors, yohimbin, 
or L-arginine) which may interact with cardiovascular 
drugs, have vasoactive or sympathomimetic eff ect, 
cause raise or reduce systemic BP, and are associated 
with adverse outcomes in patients with coronary artery 
disease72-75.
Psychological Problems and Sexual Counseling
It is necessary to estimate anxiety and depression 
because a combination of psychological disorders and 
decreased sexual function is common in CVD76-79. SA 
or pleasure often declines due to fear of patients or 
partners who believe that SA would worsen physical 
status or cause death77,80. Counseling by health profes-
sionals is necessary and useful to help patients and 
partners in restoring SA after acute cardiac event, 
newly diagnosed CVD, or after implantation of the 
ICD3,81-85. General recommendation is that patients 
should be involved in sexual activities rested, they 
should avoid unknown environment and partners in 
order to reduce stress during SA, avoid consuming 
heavy meals or alcohol before SA, and practice posi-
tions that do not restrict breathing. Each patient 
should be approached individually, since reaching or-
gasm may require greater eff ort and may not be a real-
istic initial goal in some patients.
Summary of AHA Guidelines and Conclusion
In CVD patients, complete evaluation of physical 
condition is recommended prior to involvement in SA. 
Stable symptoms and good functional capacity carry a 
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low risk of adverse cardiovascular events. In others, SA 
should be postponed until their condition is stabilized 
or optimally controlled. In subjects with doubtful risk, 
exercise stress testing can give additional information 
on the safety of SA. Cardiovascular drugs that can re-
lieve symptoms and improve survival should not be 
avoided because of the concern about their potential 
impact on sexual function.
Phosphodiesterase inhibitors are safe and eff ective 
in patients with CVD, but contraindicated during 
treatment with nitrates. Psychological conditions, such 
as anxiety and/or depression, may have infl uence on 
sexual function. Sexual counseling of both patients and 
their partners has a role in recovery of sexual function 
and habits.
Further researches of SA in certain CVDs are 
needed, especially in women and older persons. Future 
diagnostic, pharmacological and surgical guidelines for 
treating CVD patients should be much clearer in de-
fi ning for SA. It is necessary to raise awareness of a 
multidisciplinary approach, including sexual counsel-
ing as one of the most essential items in daily work 
with these patients and their partners.
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Sažetak
SEKSUALNA AKTIVNOST U BOLESNIKA SA SRČANIM BOLESTIMA
M. Mornar Jelavić, G. Krstačić, A. Perenčević i H. Pintarić
U ovom preglednom članku donosimo pregled posljednjih smjernica koje je objavilo Američko kardiološko društvo o 
seksualnoj aktivnosti u bolesnika s koronarnom bolešću, srčanom insufi cijencijom, strukturnim bolestima srca, aritmijama, 
ugrađenim elektrostimulatorom ili kardioverter defi brilatorom, kao i o mogućnostima liječenja seksualne disfunkcije. 
 Seksualna aktivnost je ekvivalent blage/umjerene tjelesne aktivnosti tijekom kratkog vremena. Za većinu bolesnika je prepo-
ručljivo da se uključe u seksualne aktivnosti nakon sveobuhvatne procjene fi zičkog stanja. Oni sa stabilnim kardijalnim 
simptomima i dobrom funkcionalnom sposobnošću imaju nizak rizik od neželjenih kardiovaskularnih događaja. Ostali 
 zahtijevaju liječenje ili stabilizaciju prije uključivanja u seksualne aktivnosti. Ergometrijsko testiranje je korisno u procjeni 
sigurnosti spolne aktivnosti u bolesnika s upitnim ili neodređenim rizikom. Liječenje seksualne disfunkcije uključuje 
 seksualno savjetovanje bolesnika i partnera te farmakološku terapiju kod muškaraca inhibitorima fosfodiesteraze (sildenafi l, 
tadalafi l, vardenafi l), koji su se pokazali sigurnima i učinkovitima, a u žena inhibitorima ponovne pohrane serotonina (fl iban-
serin) i lokalnom vaginalnom aplikacijom estrogena. Zaključno, bolesnicima u svakodnevnoj kliničkoj praksi treba pristupiti 
individualno i multidisciplinarno u cilju otkrivanja i otklanjanja čimbenika koji ometaju normalnu spolnu aktivnost i dovode 
do narušavanja kvalitete života.
Ključne riječi: Kardiovaskularne bolesti; Seksualna disfunkcija, fi ziološka – farmakoterapija; Seksualno ponašanje; Kvaliteta 
života
